ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 28.42M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 28.42M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 28.42M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 28.42M | (m) | (m) |
| 2026-03-31 | 28.42M | (m) | (m) |
| 2025-12-31 | 28.42M | (m) | (m) |
| 2025-09-30 | 28.41M | (m) | (m) |
| 2025-06-30 | 27.15M | (m) | (m) |
| 2025-03-31 | 27.12M | (m) | (m) |
| 2024-12-31 | 27.12M | (m) | (m) |
| 2024-09-30 | 27.09M | (m) | (m) |
| 2024-06-30 | 27.04M | (m) | (m) |
| 2024-03-31 | 26.93M | (m) | (m) |
| 2023-12-31 | 26.92M | (m) | (m) |
| 2023-09-30 | 26.72M | (m) | (m) |
| 2023-06-30 | 26.60M | (m) | (m) |
| 2023-03-31 | 26.56M | (m) | (m) |
| 2022-09-30 | 26.49M | (m) | (m) |
| 2022-06-30 | 26.58M | (m) | (m) |
| 2022-03-31 | 26.42M | (m) | (m) |
| 2021-12-31 | 26.38M | (m) | (m) |
| 2021-09-30 | 26.36M | (m) | (m) |
| 2021-06-30 | 26.33M | (m) | (m) |
| 2021-03-31 | 26.32M | (m) | (m) |
| 2020-12-31 | 26.28M | (m) | (m) |
| 2020-09-30 | 24.49M | (m) | (m) |
| 2020-06-30 | 24.39M | (m) | (m) |
| 2020-03-31 | 19.89M | (m) | (m) |
| 2019-12-31 | 15.14M | (m) | (m) |
| 2019-09-30 | 15.13M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |